News

Harvard College Alzheimer’s Buddies to Host Symposium on Saturday, April 18, 2015

The Harvard College Alzheimer’s Buddies (HCAB) student association is organizing an interdisciplinary symposium to encourage discussion and debate among students on the complexity of Alzheimer’s disease. The Alzheimer’s Symposium, which is open not only for students, but for anyone interested in participating, is taking place on April 18th in Cambridge, MA. The…

Low-frequency Magnetic Fields Do Not Accelerate Alzheimer’s Disease and ALS

Evidence indicates that low-frequency alternating magnetic fields generated by overhead power lines aggravate neurodegenerative disorders including Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). Nevertheless, recent research conducted by scientists from the Institute of Pathobiochemistry at the Medical Center of Johannes Gutenberg University Mainz (JGU) in Germany found no evidence…

Alzheimer’s Association Reports Lack of Disclosure on Disease Diagnosis by Healthcare Providers

The diagnosis of Alzheimer’s disease is vital for patients to plan their future, access proper healthcare services and make informed decisions regarding treatment options. However, the Alzheimer’s Association recently revealed in its 2015 Alzheimer’s Disease Facts and Figures that many individuals are being deprived from an accurate diagnosis.

US Senate Special Committee On Aging Urged To Invest In Alzheimer’s Research

The United States Senate Special Committee on Aging recently hosted a meeting entitled “The Fight Against Alzheimer’s Disease: Are We on Track to a Treatment by 2025?” The meeting featured the personal testimonies of Dr.Ronald Petersen from the Mayo Clinic, a top Alzheimer’s researcher and former member of the national Alzheimer’s Association; B. Smith,…

Alzheimer’s Disease Research, Ellison Foundation to Invest $6 Million in UW Medicine Precision Medicine Approach

Currently incurable, Alzheimer’s disease (AD) is projected by the Centers for Disease Control to afflict some 13.8 million people in the U.S. by 2050 if effective new treatments are not discovered. Already, millions of U.S. residents are living with severe, disabling, and progressively degenerative Alzheimer’s-related dementia. Dr. Thomas…

Amarantus Will Present At The Neurotech Investing And Partnering Conference, April 2015

Amarantus BioSciences Holdings, Inc., a biotechnology firm advancing diagnostic and therapeutic products for orphan diseases in the areas of neurology, ophthalmology, psychiatry and regenerative medicine, recently announced that Mr. Gerald E. Commissiong, CEO and President, will be presenting at the Neurotech Investing and Partnering Conference being held at the Hotel Nikko…